PT-141 and sexual desire: what the evidence says and what it does

PT-141 y el deseo sexual: qué dice la evidencia y qué efectos tiene

There is a conversation almost nobody has out loud. Not at the doctor's office, not at home, sometimes not even with a partner.

It's the one about desire that left. Not a bad day, not a heavy week. The kind that's been gone for months — that used to be there and isn't — and that, on top of everything, bothers you that it's gone.

That last part — that it bothers you — is what turns a normal change in life into something medicine actually studies. And around that, a peptide showed up with a code name that sounds like an experiment: PT-141. Here are the real numbers, without promises and without drama.

Educational content. Not medical advice. Results vary.

What PT-141 is, and why it's unlike anything else

Almost everything you know about treating the sexual side works on the plumbing. Sildenafil-type medications open blood vessels, improve blood flow and make a physical response easier. They work on the body.

PT-141 does something different. It's a cyclic peptide — a short chain of amino acids — that acts on melanocortin receptors in the central nervous system. Upstream, in the brain. On the pathways that have to do with wanting, not with circulation.

That difference isn't textbook trivia. It explains why it was studied for a problem sildenafil never solved: the person whose body responds fine, but who simply has no interest.

Its pharmaceutical name is bremelanotide. PT-141 is the development code, and it's still the name it's sold under in the peptide world.

The "melanocortin" part is worth holding on to: it's the same receptor family that regulates skin pigment. We'll come back to that, because it's where one of the least-discussed effects lives.

The problem it's meant to solve has a name

In medicine it's called hypoactive sexual desire disorder, or HSDD. It isn't diagnosed just by having low desire.

For the definition the trials used, several things have to be true at the same time:

• Acquired: you didn't have this problem before. It's a change, not how you've always been.
• Generalized: it happens regardless of the type of stimulation, the situation or the partner. Not just with one person or in one context.
• With distress: it causes real personal distress or difficulty in the relationship. If it doesn't bother you, it isn't a disorder — it's just where you are.
• Not explained by something else: not due to a coexisting medical or psychiatric condition, a relationship problem, or the effect of a medication or drug.

That last point is the one most people skip. An antidepressant, an uncontrolled thyroid, sustained stress, untreated pain, a conflict at home — all of them lower desire, and none of them is fixed by a peptide. That's why the medical evaluation comes before anything else.

The two trials that got it approved

They were called RECONNECT. Two identical phase 3 studies — randomized, double-blind, placebo-controlled. The most demanding design there is.

The basic numbers: 1,267 premenopausal women, split by chance into two groups, half product and half placebo, for 24 weeks. Mean age 39. 96.6% at U.S. sites.

They measured two main things, decided before the trials began — which matters, because it stops anyone from picking the prettiest result at the end:

• Desire, using the desire domain of the Female Sexual Function Index.
• Distress tied to that low desire, using item 13 of the Female Sexual Distress Scale.

The result: on both measures, the product beat placebo with statistical significance. Desire rose 0.35 points more than placebo in the integrated analysis, and distress fell 0.33 points more.

A later analysis, published in 2022, checked whether the effect held across subgroups: by age, weight, body mass index and bioavailable testosterone. It held in nearly all of them, with few exceptions. It also held with and without hormonal contraceptives.

That's a good sign of consistency. An effect that shows up in only one subgroup is usually noise. One that shows up across all of them is usually real.

What a 0.35 on a scale actually means

This is where most articles stop and say "statistically significant," as if that settled it. It doesn't.

"Statistically significant" means: this result is very unlikely to be chance. It does not mean: this result is large, or that you'll feel it.

The desire scale runs roughly from 1.2 to 6. A 0.35 change on that scale is, honestly, small on average. Nobody reading it should picture a transformation.

But there's a nuance in its favor. Before phase 3, the researchers did something careful: they defined in advance what change would be clinically meaningful to a patient — not just statistically — using several methods, including expert estimates and analysis curves based on what the women themselves reported as benefit.

Using those definitions, in the earlier dose-ranging study, the share of women who reached a genuinely meaningful change was higher with the product than with placebo, across all seven endpoints measured.

Translated: the average is modest because some women got almost nothing and some got something real. The average blends them together. That's the honest reading.

What the women said in their own words

A detail that rarely gets told: when the blinded part of RECONNECT ended, and before anyone learned what they'd been given, the participants were interviewed.

242 women completed an exit survey and 80 also did a longer telephone interview. They still didn't know whether they'd received the product or placebo.

The ones who had received the product described more desire, more physical arousal, and better overall quality of sexual activity with their partner.

The ones who had received placebo reported benefits too — but of a different kind: feeling good about having sought help, and communicating better with their partner about it. They didn't describe the physical changes.

That difference is more interesting than any number. It shows that a real part of the benefit of addressing the problem doesn't come from the medication. It comes from no longer ignoring it.

The side effects, unvarnished

This is the part peptide sellers put in small print. Here it's in large print, exactly as it appears in the FDA-approved prescribing information.

• Nausea: 40%. Four in ten. 13% needed anti-nausea medication and 8% discontinued because of it. For most, it improved with the second dose.
• Flushing: 20%, versus under 1% on placebo. None of the events were serious and few were severe, but 1% left the study over it.
• Headache: among the effects occurring in 10% or more in both trials.
• A transient rise in blood pressure after each dose, usually resolving within 12 hours, along with a fall in heart rate.

That last point changes the conversation for a lot of people. If you have uncontrolled high blood pressure or known cardiovascular disease, this product isn't for you — and that isn't a box-ticking precaution.

The dark patches: why this matters more in darker skin

Back to the melanocortin receptors. Those receptors also regulate pigment. Stimulate them and a fraction of people develop darkening of the skin in specific areas.

In the prescribing information it appears in 1% of patients who used up to 8 doses per month, with cases involving the face, the gums and the breasts.

And here's the line that rarely makes it into the summary: the risk is higher in patients with darker skin and with daily dosing.

For a lot of our community that isn't a footnote. It's information that changes the decision. If you already live with dark patches, melasma, or hyperpigmentation after a pregnancy, this is a fact your physician needs on the table beforehand, not after.

It doesn't mean it happens to everyone. It means that 1% doesn't spread evenly across every skin tone.

What about men?

It's the most common question, and it deserves a direct answer: it is not approved for men.

That doesn't mean it was never studied. In 2004 a study was published on the intranasal version of PT-141 in healthy men and in men with mild-to-moderate erectile dysfunction who responded to sildenafil.

That study found an erectile response statistically superior to placebo at doses above 7 mg, with the first response at roughly 30 minutes. The most common effects were, once again, flushing and nausea.

It was a phase 1 study, with few participants, in a nasal format that doesn't exist on the market today. It's a data point from more than twenty years ago, not an approval.

What exists today for men, with evidence and approval, is still something else. And if a man's problem is desire rather than erection, the first things a reasonable physician reviews are testosterone, sleep, stress, medications and mood. In that order.

How the approved product is used

So you have the full picture, here's what the approved label says:

• 1.75 mg subcutaneously, in the abdomen or thigh.
• As needed, at least 45 minutes before anticipated sexual activity.
• No more than one dose in 24 hours.
• More than 8 doses per month is not recommended.

That "as needed" is part of the design. It isn't a daily treatment and it isn't something that builds up over time.

What this evidence does NOT say

With the same care we used for what it does show:

• It doesn't say it works in men. The 2004 study was phase 1, nasal, with few participants, and the male program never reached approval.
• It doesn't say it works after menopause. The trials enrolled premenopausal women and the approved indication expressly excludes postmenopausal women.
• It doesn't say it increases how often you have sex. The two main endpoints were desire and distress, not frequency.
• It doesn't say it fixes a relationship problem. The definition of the disorder explicitly excludes those cases.
• It says nothing about use over many years. The trials measured 24 weeks, with an optional 52-week open-label extension.
• It doesn't say pharmacy-prepared versions are the same as the approved product. Everything you just read comes from the product that went through the FDA.

Who is this NOT for?

• People with uncontrolled high blood pressure or known cardiovascular disease.
• Postmenopausal women: not the population studied, not the approved indication.
• Men: not approved.
• Anyone with another identifiable cause of low desire — thyroid, depression, a medication, pain, exhaustion — that hasn't been treated yet.
• Anyone pregnant or trying to conceive, without discussing it with their physician first.
• Anyone with a strong history of hyperpigmentation who isn't willing to accept that risk.
• Anyone expecting a one-shot fix for something that took years to build.

Frequently asked questions

Is PT-141 the same as Vyleesi?

The active ingredient is the same: bremelanotide. Vyleesi is the finished product the FDA approved in June 2019, with its dose, its autoinjector and its safety data. "PT-141" is the development code, and it's also the name pharmacy-prepared versions circulate under — versions that are not the approved product. They are not interchangeable in terms of evidence.

How long does it take to work?

The approved label says to give it at least 45 minutes before anticipated sexual activity. It isn't something you take daily waiting for it to build up.

Does the nausea go away?

In the trials, it improved for most women with the second dose. Even so, 13% needed anti-nausea medication and 8% dropped out because of it. It's the effect people most underestimate.

Can I use it on hormonal birth control?

The 2022 subgroup analysis found reduced distress both with and without hormonal contraceptives, and a statistically significant increase in desire in women not using them, with a numerical advantage in those who were. That decision belongs to your physician, with your full history.

Does it raise blood pressure?

Yes, transiently after each dose, usually resolving within about 12 hours. That's why it isn't recommended with uncontrolled high blood pressure or known cardiovascular disease.

What if my problem is exhaustion, not low desire?

Then the starting point is different. Sleep, thyroid, iron, sustained stress and mood lower desire far more often than any melanocortin receptor. Starting there isn't settling — it's starting where the problem actually is.

How we handle this at SCTS1

Our position here is the same as always, and it's an awkward one for selling: most people who ask about a peptide for desire don't need the peptide first. They need someone to look at the whole picture.

That's why the order matters. Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary. That physician decides what fits and what doesn't, including the possibility that the answer is "this isn't for you."

We offer clinician-supervised hormone health and weight management programs, and GLP-1 programs with FDA-approved medications (Wegovy®, Foundayo™, Ozempic®) from $149 per month, by telemedicine, in Spanish and English.

Eligibility is determined by medical evaluation. Individual results vary and are not guaranteed.

Sources

Articles located through PubMed.

• Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. 10.1097/AOG.0000000000003500
• Simon JA, Kingsberg SA, Portman D, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health. 2022;31(3):391-400. 10.1089/jwh.2021.0225
• Althof S, Derogatis LR, Greenberg S, et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019;16(8):1226-1235. 10.1016/j.jsxm.2019.05.012
• Koochaki P, Revicki D, Wilson H, et al. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. J Womens Health. 2021;30(4):587-595. 10.1089/jwh.2020.8460
• Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-59. 10.1038/sj.ijir.3901139
• FDA — VYLEESI (bremelanotide injection) — Highlights of Prescribing Information. Initial U.S. approval 2019. accessdata.fda.gov

Your trust is worth more than a sale.

More information →

This article is informational and is not medical advice. SCTS1 does not prescribe medications. All medical care, prescriptions and treatment plans are provided by licensed physicians through our partner platform. Eligibility is determined by a licensed provider. Bremelanotide (Vyleesi) is FDA-approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder; it is not approved for men or for postmenopausal women, and any other use is off-label and is mentioned here for informational purposes only. Individual results vary and are not guaranteed.